Navigation Links
Sonic Hedgehog variations linked to recurrence, survival and response to therapy of bladder cancer
Date:12/9/2009

HOUSTON - Genetic variations in the Sonic Hedgehog pathway increase the likelihood of recurrence, reduce survival time and limit response to therapy for people with non-muscle invasive bladder cancer, scientists from The University of Texas M. D. Anderson Cancer Center reported today at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

"These variations are strongly associated with response to standard immunotherapy that patients receive after tumor resection," said senior author Xifeng Wu, M.D. Ph.D., professor in M. D. Anderson's Department of Epidemiology. "Discovering the genetic aspects of bladder cancer risk is another step toward personalized cancer therapy. We are combining genetic and epidemiological information to build a model that predicts bladder cancer risk and helps guide treatment in the clinic."

Patients who had zero or one of five GLI3 variations associated with response to the Bacillus Calmette-Guerin (BCG) immunotherapy to prevent recurrence had a mean recurrence-free survival time of 114.7 months compared with 9.9 months for those with two-to-five variations.

The Sonic Hedgehog cell signaling pathway plays an important role in embryonic development and stem cell maintenance.

"Abnormal activation of this pathway has been implicated in development of various cancers and progression to metastasis, so we hypothesized that genetic variations might affect bladder cancer patients' clinical outcomes," said Meng Chen, Ph.D., the study's first author.

The team evaluated 494 non-muscle invasive bladder cancer patients for 151 single nucleotide polymorphisms - variations of a single DNA building block in a gene - in nine genes in the pathway.

Patients with non-muscle invasive disease comprise 70-80 percent of all bladder cancer cases. They have a high recurrence rate, at 70 percent, but only 10-15 percent have their disease progress to the invasive stage.

The researchers found a variation in the GLI2 gene that was associated with a doubling of risk of recurrence. Patients with the variation had recurrence-free median survival time of 7.6 months compared to 16.7 months for those without the variation.

Five variations of the GLI3 gene produced the strong response to BCG immunotherapy.

There were no significant effects found in an analysis of 319 patients with invasive-muscle disease.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Ultrasonic Cleaner from Tovatech Plays Key Role in World Health Organization's Guidelines for Infection Control
2. VisualSonics Appoints New President and CEO
3. Brooke Burke Debuts Limited Edition Couture Clarisonic on Ultimate Style Stage: The SGK Pink Dress Runway at New York Fashion Week
4. Misonix Expands Sales Organization for Direct Sales of the SonicOne(TM) Wound Management System and the SonaStar(R) Ultrasonic Surgical Aspirator in the United States
5. Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush
6. Sonic Innovations Awarded Contract From U.S. Veterans Administration
7. Otix Global, Inc. to Become Parent Company of Sonic Innovations, Inc.
8. Clarisonic Pounds the Pavement Pink Offering Generous Donation at 2009 Entertainment Industry Foundation Revlon Run/Walk for Women
9. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
10. Sonic Innovations Celebrates Companys First Receiver-In-Canal Hearing Aid
11. SonicWALL Delivers Flexible High-Performance Threat Management for ZirMed
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sonic Hedgehog variations linked to recurrence, survival and response to therapy of bladder cancer
(Date:8/17/2017)... ... August 17, 2017 , ... ... Group, a Florida-based oncology business advisor to oncology practices, announced today the results ... amount of attributable savings from resolving critical clinical issues that would have otherwise ...
(Date:8/16/2017)... ... August 16, 2017 , ... The next Patient Care Academy at Kalamazoo Valley ... who successfully complete the seven-week long Patient Care Academy are eligible to take the ... salary for a CNA in Kalamazoo is $24,428.* , As a CNA, one is ...
(Date:8/16/2017)... ... August 16, 2017 , ... An August 3rd article on Reuters covers ... of a report in JAMA (the Journal of the American Medical Association). The study found ... to achieve BMIs under 30, when compared to patients with lower BMIs. At present, weight ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Ten outstanding ... Union's Stars in the Classroom and will win a visit by a Houston Texans ... K-12 who are at least five years old can visit texanschecking.com/stars to nominate their ...
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test ... The company ranked #4429 on the newly released, 36th annual Inc. 5000 , ... unique look at the most successful companies within the American economy’s most dynamic segment ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... -- E.I. Medical Imaging (EIMI) has partnered with Dr. ... the worlds first ultrasound system to be used underwater to ... In preparation for a piece produced by Icon films ... Guttridge approached EIMI with the idea of an underwater ultrasound ... underwater. EIMI produces ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... Massachusetts , July 25, 2017 The med-tech ... rare nervous system diseases, has concluded a worldwide license agreement ... drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement ... a Phase 2 study conducted in Europe ... the United States ...
Breaking Medicine Technology: